About NFL Biosciences

Company Description

Making it possible to cure smoking addiction

NFL Biosciences develops a naturally based addiction withdrawal solution to help smokers willing to quit in their battle for a healthier life.

NFL Biosciences is a biotechnology company pioneering innovative solutions through a breakthrough approach based on a standardized extract of tobacco leaf. NFL-101 is NFL Biosciences current core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

Year founded

2006

Served area

Worldwide

Headquarters

199 Rue Hélène Boucher, 34170 Castelnau-le-Lez – France

Shareholder information

Shares outstanding

5,234,612

IPO

July 5, 2021

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.